Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ipsen
  6. Summary
    IPN   FR0010259150

IPSEN

(IPN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
86.56(c) 86.24(c) 85.54(c) 86.68(c) 87.54(c) Last
75 248 91 038 67 100 166 500 88 153 Volume
+0.35% -0.37% -0.81% +1.33% +0.99% Change
More quotes
Estimated financial data (e)
Sales 2021 2 812 M 3 270 M 3 270 M
Net income 2021 611 M 710 M 710 M
Net Debt 2021 57,7 M 67,1 M 67,1 M
P/E ratio 2021 12,0x
Yield 2021 1,17%
Sales 2022 2 835 M 3 296 M 3 296 M
Net income 2022 591 M 687 M 687 M
Net cash position 2022 450 M 523 M 523 M
P/E ratio 2022 12,4x
Yield 2022 1,18%
Capitalization 7 200 M 8 374 M 8 372 M
EV / Sales 2021 2,58x
EV / Sales 2022 2,38x
Nbr of Employees 5 703
Free-Float 41,9%
More Financials
Company
Ipsen SA is a France-based biopharmaceutical group specialized in specialty care. The Company operates globally through two segments: Specialty Care and Consumer Healthcare. In Specialty Care, the Company is focused on various therapeutic areas, including oncology, neurosciences and rare diseases. Its oncology portfolio includes Somatuline, Decapeptyl, Cabometyx and Onivyde. Its neuroscience portfolio includes... 
Sector
Pharmaceuticals
Calendar
02/17Earnings Release
More about the company
Ratings of Ipsen
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about IPSEN
10/21GLOBAL MARKETS LIVE : Tesla, Unilever, Paypal, Elliott, Novartis...
10/21IPSEN : Lifts FY21 Sales Growth Guidance to At Least 11%
MT
10/21IPSEN : Strong results in Q3 as we Focus. Together. For patients �...
PU
10/21Ipsen S.A. Reports Unaudited Sales Results for the Third Quarter and Nine Months Ended ..
CI
10/21Ipsen S.A. Revises Sales Guidance for the Year 2021
CI
10/18IPSEN : Signs $446 Million Deal With Accent Therapeutics To Develop Blood, Bone Marrow Can..
MT
10/18IPSEN : Accent collaboration – 18 October 2021
PU
10/18Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclu..
CI
10/12REUTERS EVENTS PHARMA 2021 : Transforming Medical Affairs to ...
PU
10/11Ipsen Appoints Mari Scheiffele as EVP and President, Specialty Care International, Effe..
CI
10/01IPSEN : Rethinking risk factors this Liver Cancer Awareness Month
PU
09/29IPSEN : Q3 Results – Conference Call – October 21, 2021
PU
09/20IPSEN : ESMO 2021, Cabometyx demonstrates sustained 78% reduction in risk of disease progr..
AQ
09/20MIRATI THERAPEUTICS : taps industry veteran Meek as CEO
RE
09/20IPSEN : Thyroid Cancer Drug Shows Sustained Effect In Late-Stage Study
MT
More news
News in other languages on IPSEN
10/21Résumé des principales informations économiques du jeudi 21 octobre
10/21IPSEN : De solides résultats au troisième trimestre
10/21Ipsen relève ses prévisions de croissance des ventes pour l'exercice 21 à au moins 11 %..
10/21IPSEN : objectifs pour 2021 revus en hausse
10/21Le laboratoire Ipsen relève ses objectifs 2021 pour la 2e fois
More news
Analyst Recommendations on IPSEN
More recommendations
Stock Trading Strategies
IPSEN - 03/31
Helped by a technical support level
BUY
More Stock Trading Analysis
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | IPN | FR0010259150 | MarketScreener
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 87,54 €
Average target price 94,06 €
Spread / Average Target 7,45%
EPS Revisions
Managers and Directors
David G. Loew Chief Executive Officer & Director
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Marc M. P. de Garidel Non-Executive Chairman
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
IPSEN28.92%8 374
JOHNSON & JOHNSON4.03%430 990
ROCHE HOLDING AG15.15%337 974
NOVO NORDISK A/S58.77%242 392
PFIZER, INC.16.44%241 985
ELI LILLY AND COMPANY44.37%220 979